文献速递泌尿生殖与妇科肿瘤放疗

奈非那韦未改善PC-3前列腺癌分次照射疗效

The HIV protease and PI3K/Akt inhibitor nelfinavir does not improve the curative effect of fractionated irradiation in PC-3 prostate cancer in vitro and in vivo.
PubMed 文献 · Clin Transl Radiat Oncol · 2017-01-05

该研究在PC-3前列腺癌细胞中体外测试奈非那韦(10 μM)对放射反应的影响,并在裸鼠移植瘤中测试奈非那韦(80 mg/kg,每周5天,共6周)联合分次照射(30次,总剂量30-120 Gy)的疗效。结果显示奈非那韦抑制Akt Ser473磷酸化,但体外克隆存活率略高,体内单药未显著延长肿瘤生长时间,也未改善局部肿瘤控制。

要点

  • 奈非那韦抑制PC-3细胞Akt Ser473磷酸化,但未增强放射敏感性。
  • 体外联合处理克隆存活率略高,提示无放疗增敏效应。
  • 体内单药或联合照射均未改善肿瘤生长时间与局部控制。

核心结论

  • 奈非那韦对PC-3前列腺癌细胞无或仅有轻微敏感性,体外和体内均未观察到放射增敏效应。

研究设计与样本

  • 体外采用克隆形成实验测试10 μM奈非那韦对PC-3细胞放射反应的影响。
  • 体内采用携带PC-3移植瘤的裸鼠,奈非那韦80 mg/kg体重,每日一次,每周5天,共6周。
  • 同步照射30次,总剂量30-120 Gy,计算治疗后第180天局部肿瘤控制。

主要发现

  • 奈非那韦抑制Akt Ser473磷酸化。
  • 体外联合处理克隆存活率略高,差异微小但显著。
  • 体内奈非那韦单药未显著延长肿瘤生长时间。
  • 体内奈非那韦单药或联合照射均未改善局部肿瘤控制。

临床怎么用

  • PC-3前列腺癌模型中奈非那韦未显示放射增敏作用,不支持其用于该亚型放疗增敏。

局限性

  • 仅使用PC-3单一细胞系和裸鼠移植瘤模型,结论不能外推至其他前列腺癌模型或临床。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiotherapy has a high curative potential in localized prostate cancer, however, there are still patients with locally advanced tumours who face a considerable risk of recurrence. Radiosensitization using molecular targeted drugs could help to optimize treatment for this high-risk group. The PI3K/Akt pathway is overexpressed in many prostate cancers and is correlated to radioresistance. Nelfinavir, an HIV protease inhibitor (HPI), was found to block this pathway and to radiosensitize cancer cells of different origin. This is the first study examining the effect of nelfinavir in combination with irradiation on prostate cancer cell survival in vitro as well as on growth time and local tumour control in vivo. METHODS: The in vitro effect of nelfinavir on radioresponse of PC-3 was tested by colony formation assay with 10 μM nelfinavir. In vivo, the effect of nelfinavir alone and in combination with irradiation was tested in nude mice carrying PC-3 xenografts. For evaluating tumour growth time, mice were treated with 80 mg nelfinavir/kg body weight, daily at 5 days per week over 6 weeks. Simultaneous irradiation with 30 fractions and total doses between 30 and 120 Gy was applied to calculate local tumour control for day 180 after treatment. RESULTS: Nelfinavir inhibited Akt phosphorylation at Ser473 and showed a minor but significant effect on clonogenic cell survival in vitro with slightly higher cell survival rates after combined treatment. The treatment of PC-3 xenografts with nelfinavir alone led to no significant increase of tumour growth time and no improvement of local tumour control. CONCLUSIONS: Despite promising growth delay effects of nelfinavir in other tumour models and first clinical applications of this drug as anti-cancer agent, PC-3 prostate cancer cells express no or only minor sensitivity to nelfinavir treatment alone and no radiosensitizing effect in vitro or in vivo.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Liebscher S, Koi L, Löck S, et al. The HIV protease and PI3K/Akt inhibitor nelfinavir does not improve the curative effect of fractionated irradiation in PC-3 prostate cancer in vitro and in vivo. Clin Transl Radiat Oncol. 2017. PMID: 29657993. doi:10.1016/j.ctro.2016.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。